Premature Labor (Tocolysis) - Pipeline Review, H1 2016

Published: Mar, 2016 | Pages: 59 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Premature Labor (Tocolysis) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Premature Labor (Tocolysis) - Pipeline Review, H1 2016', provides an overview of the Premature Labor (Tocolysis) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Premature Labor (Tocolysis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Premature Labor (Tocolysis) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Premature Labor (Tocolysis)
- The report reviews pipeline therapeutics for Premature Labor (Tocolysis) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Premature Labor (Tocolysis) therapeutics and enlists all their major and minor projects
- The report assesses Premature Labor (Tocolysis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Premature Labor (Tocolysis)

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Premature Labor (Tocolysis)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Premature Labor (Tocolysis) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Premature Labor (Tocolysis) Overview 7
Therapeutics Development 8
Pipeline Products for Premature Labor (Tocolysis) - Overview 8
Pipeline Products for Premature Labor (Tocolysis) - Comparative Analysis 9
Premature Labor (Tocolysis) - Therapeutics under Development by Companies 10
Premature Labor (Tocolysis) - Therapeutics under Investigation by Universities/Institutes 11
Premature Labor (Tocolysis) - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Premature Labor (Tocolysis) - Products under Development by Companies 15
Premature Labor (Tocolysis) - Products under Investigation by Universities/Institutes 16
Premature Labor (Tocolysis) - Companies Involved in Therapeutics Development 17
AMAG Pharmaceuticals, Inc. 17
GlaxoSmithKline Plc 18
Juniper Pharmaceuticals, Inc. 19
Kissei Pharmaceutical Co., Ltd. 20
Lipocine Inc. 21
ObsEva SA 22
Premature Labor (Tocolysis) - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
AT-814 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
bedoradrine sulfate - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
hydroxyprogesterone caproate - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
hydroxyprogesterone caproate long acting - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
OBE-001 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
OBE-002 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
progesterone - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
retosiban - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small Molecule to Agonize Progesterone Receptor for Preterm Birth - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecules for Premature Labor - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Premature Labor (Tocolysis) - Recent Pipeline Updates 44
Premature Labor (Tocolysis) - Dormant Projects 49
Premature Labor (Tocolysis) - Discontinued Products 50
Premature Labor (Tocolysis) - Product Development Milestones 51
Featured News & Press Releases 51
Feb 16, 2016: Lipocine Reports Positive Results of Multi-Dose Pharmacokinetic Study of LPCN 1107 for the Prevention of Preterm Birth in Pregnant Women 51
Jan 11, 2016: Juniper Pharmaceuticals provides Update on JNP-0301 51
Nov 04, 2015: ObsEva Presents Pharmacology Data Showing that OBE002, the First Orally Active Prostaglandin F2a Antagonist, is devoid of the side effects associated with NSAID treatment of Preterm Labor 52
Sep 01, 2015: ObsEva Presents Pharmacology Data Showing that OBE001, the First Orally Active Oxytocin Antagonist, Inhibits not only Uterine Contractions but also Preterm Labor Related Inflammation Pathways 52
Jun 23, 2015: ObsEva Announces Recruitment of the First Patient in TERM Phase 2 Study - Clinical Trial to Evaluate the Safety and Efficacy of OBE001 for Delaying Spontaneous Preterm Labor in Pregnant Women 53
Mar 17, 2015: GSK announces start of phase III programme to evaluate retosiban for spontaneous preterm labour 54
Feb 26, 2015: ObsEva Reports Positive Phase 1 Results for the First Orally Active Oxytocin Antagonist OBE001 to Treat Preterm Labour 54
Feb 27, 2012: Watson Receives Complete Response Letter From FDA For Progesterone Vaginal Gel 8% 55
Feb 09, 2012: Faruqi & Faruqi, LLP Announces Investigation Of Columbia Laboratories 56
Jan 20, 2012: FDA Advisory Committee Declines To Recommend Approval Of Watson's Progesterone Vaginal Gel 8% For Reduction Of Risk Of Preterm Birth In Women With Short Uterine Cervical Length 56
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59

List of Tables

Number of Products under Development for Premature Labor (Tocolysis), H1 2016 8
Number of Products under Development for Premature Labor (Tocolysis) - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Development, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Premature Labor (Tocolysis) - Pipeline by AMAG Pharmaceuticals, Inc., H1 2016 17
Premature Labor (Tocolysis) - Pipeline by GlaxoSmithKline Plc, H1 2016 18
Premature Labor (Tocolysis) - Pipeline by Juniper Pharmaceuticals, Inc., H1 2016 19
Premature Labor (Tocolysis) - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2016 20
Premature Labor (Tocolysis) - Pipeline by Lipocine Inc., H1 2016 21
Premature Labor (Tocolysis) - Pipeline by ObsEva SA, H1 2016 22
Assessment by Monotherapy Products, H1 2016 23
Number of Products by Stage and Target, H1 2016 25
Number of Products by Stage and Mechanism of Action, H1 2016 27
Number of Products by Stage and Route of Administration, H1 2016 29
Number of Products by Stage and Molecule Type, H1 2016 31
Premature Labor (Tocolysis) Therapeutics - Recent Pipeline Updates, H1 2016 44
Premature Labor (Tocolysis) - Dormant Projects, H1 2016 49
Premature Labor (Tocolysis) - Discontinued Products, H1 2016 50